The current valuation multiples appear to be pricing in a cyclical trough rather than a structural impairment, as the forward P/E is less than half the trailing P/E of 17.78. However, the PEG ratio of 1.64 indicates that even at these depressed levels, the stock is not cheap relative to its near-term growth prospects. The market is likely waiting for evidence of margin stabilization or a return to organic growth before re-rating the multiple.

The divergence between gross and operating margins suggests that Globant's cost structure has become bloated, likely from aggressive hiring and studio expansion during the growth phase. The 7% operating margin cited in the intelligence blocks appears to be a trailing average, masking the recent quarterly deterioration to 3.2%. This level of profitability is insufficient to generate meaningful returns on capital and leaves little buffer for further revenue softness.

The ROIC trend is particularly concerning when viewed alongside the $1.6B goodwill balance, which represents half of total assets. With ROIC now well below the company's estimated cost of capital, the market is right to question whether past acquisitions have been value-accretive. The low ROE of 0.1% in Q2 2026 confirms that the business is barely generating a return for equity holders, a stark reversal from the 2.5% ROE seen just two years ago.

The low leverage provides significant financial flexibility for M&A, but the current environment of stagnant growth and compressed margins makes this a poor time for debt-funded acquisitions. Interest coverage of 1.47x in Q2 2026 is adequate but has deteriorated sharply from 8.21x in Q4 2025, indicating that even modest debt is becoming more burdensome as operating income declines. The balance sheet is healthy, but it is not being used to drive returns.